Adocia SA (EPA:ADOC)

Market Cap	79.54M
Revenue (ttm)	12.12M
Net Income (ttm)	-9.32M
Shares Out	18.08M
EPS (ttm)	-1.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	743,751
Average Volume	166,414
Open	4.480
Previous Close	4.400
Day's Range	4.400 - 5.190
52-Week Range	2.860 - 10.960
Beta	0.47
RSI	69.51
Earnings Date	Apr 17, 2025

About Adocia

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company’s clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and ra...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 78
• Stock Exchange: Euronext Paris
• Ticker Symbol: ADOC

Financial Performance

In 2024, Adocia's revenue was 12.12 million, an increase of 100.43% compared to the previous year's 6.05 million. Losses were -9.32 million, -55.95% less than in 2023.